Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor XIII - CSL Behring

Next Previous
Search
Drug Profile

Factor XIII - CSL Behring

Alternative Names: Blood coagulation factor XIII - CSL Behring; Coagulation factor XIII - CSL Behring; Corifact; Fibrin stabilising factor - CSL Behring; Fibrogammin-P

Latest Information Update: 24 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; University College London
  • Class Antihaemorrhagics; Blood coagulation factors
  • Mechanism of Action Factor XIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Factor XIII deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Factor XIII deficiency; Surgical blood loss
  • Discontinued Systemic scleroderma

Most Recent Events

  • 24 Sep 2021 Discontinued - Phase-II for Systemic scleroderma (Adjunctive treatment) in United Kingdom (IV)
  • 28 Feb 2013 Launched for Surgical blood loss in USA (IV)
  • 28 Feb 2013 Registered for Surgical blood loss in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top